International Journal of Radiation Oncology * Biology * Physics
Volume 80, Issue 3 , Pages 698-704 , 1 July 2011

Patterns of Response After Preoperative Treatment in Gastric Cancer

Presented in part at the 50th Annual Meeting of the American Society for Radiation Oncology, September 21–25, 2008, Boston, MA.

  • Juan A. Díaz-González, M.D.

      Affiliations

    • Division of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
    • Corresponding Author InformationReprint requests to: Juan A. Díaz-González, M.D., Department of Oncology, Clinica Universidad de Navarra, Avda. Pio XII 36, Pamplona 31008. Spain. Tel: (+34) 948-255-400; Fax: (+34) 948-255-500
    • ,
  • Javier Rodríguez, M.D.

      Affiliations

    • Division of Medical Oncology, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain
    • ,
  • José L. Hernández-Lizoain, M.D.

      Affiliations

    • Department of Surgery, Clínica Universidad de Navarra, Pamplona, Spain
    • ,
  • Raquel Ciérvide, M.D.

      Affiliations

    • Division of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
    • ,
  • Miren Gaztañaga, M.D.

      Affiliations

    • Division of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
    • ,
  • Iñigo San Miguel, M.D.

      Affiliations

    • Division of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
    • ,
  • Leire Arbea, M.D.

      Affiliations

    • Division of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
    • ,
  • J. Javier Aristu, M.D.

      Affiliations

    • Division of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
    • ,
  • Ana Chopitea, M.D.

      Affiliations

    • Division of Medical Oncology, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain
    • ,
  • Fernando Martínez-Regueira, M.D.

      Affiliations

    • Department of Surgery, Clínica Universidad de Navarra, Pamplona, Spain
    • ,
  • Víctor Valentí, M.D.

      Affiliations

    • Department of Surgery, Clínica Universidad de Navarra, Pamplona, Spain
    • ,
  • Jesús García-Foncillas, M.D.

      Affiliations

    • Division of Medical Oncology, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain
    • ,
  • Rafael Martínez-Monge, M.D.

      Affiliations

    • Division of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
    • ,
  • Jesús J. Sola, M.D.

      Affiliations

    • Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain

Received 30 December 2009 ,Revised 24 February 2010 ,Accepted 3 March 2010.

References 

  1. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908–914
  2. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer. 2000;88:921–932
  3. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003;21:3647–3650
  4. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: Ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228:449–461
  5. Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20
  6. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24:3953–3958
  7. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23:1237–1244
  8. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521–1530
  9. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692–4698
  10. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851–856
  11. Krempien R, Muenter MW, Harms W, Debus J. Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma. HPB (Oxford). 2006;8:22–28
  12. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl.J Med. 2004;351:1731–1740
  13. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–467
  14. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–730
  15. Kim S, Lim DH, Lee J, Kang WK, Macdonald JS, Park CH, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005;63:1279–1285
  16. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218:583–592
  17. Willett C, Gunderson LL. Stomach. In:  Halperin EC,  Perez CA,  Brady LW editor. Perez and Brady's principles and practice of radiation oncology. 5th ed.. Philadelphia: Lippincott Williams & Wilkins; 2008;p. 1322
  18. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330–4337
  19. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347–1355
  20. Diaz-Gonzalez JA, Calvo FA, Cortes J, Garcia-Sabrido JL, Gomez-Espi M, Del Valle E, et al. Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. Int J Radiat Oncol Biol Phys. 2006;64:1122–1128
  21. Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241:829–838
  22. Janjan NA, Abbruzzese J, Pazdur R, Khoo VS, Cleary K, Dubrow R, et al. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol. 1999;51:153–160
  23. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688–8696
  24. Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A, et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys. 2002;53:664–674
  25. Crookes P, Leichman CG, Leichman L, Tan M, Laine L, Stain S, et al. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: A final report. Cancer. 1997;79:1767–1775
  26. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774–2780
  27. Kaminsky-Forrett MC, Conroy T, Luporsi E, Peiffert D, Lapeyre M, Boissel P, et al. Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer. Int J Radiat Oncol Biol Phys. 1998;42:935–941
  28. Vogel SB, Mendenhall WM, Sombeck MD, Marsh R, Woodward ER. Downstaging of esophageal cancer after preoperative radiation and chemotherapy. Ann Surg. 1995;221:685–693
  29. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680–2686
  30. Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: Implications for response classification. Ann Surg. 2005;242:684–692
  31. Shia J, Guillem JG, Moore HG, Tickoo SK, Qin J, Ruo L, et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol. 2004;28:215–223
  32. Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:752–760
  33. Tepper JE, O'Neil B. Transition in biology and philosophy in the treatment of gastroesophageal junction adenocarcinoma. J Clin Oncol. 2009;27:836–837

 Conflict of interest: J.M. Garcia-Foncillas is a consultant with Roche Pharmaceuticals Division and with Sanofy-Aventis. J.M. Garcia-Foncillas has received research grants from Sanofy-Aventis and from Roche.

PII: S0360-3016(10)00421-9

doi: 10.1016/j.ijrobp.2010.02.054

International Journal of Radiation Oncology * Biology * Physics
Volume 80, Issue 3 , Pages 698-704 , 1 July 2011

Article Tools